ENDRA Life Sciences Inc. current report, 27 March 2020

ENDRA Life Sciences Inc. - Form 8-K Summary

Business Context and Reporting Period

ENDRA Life Sciences Inc., a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on March 27, 2020. The report details the entry into a material definitive agreement to facilitate equity financing.

Key Financial Metrics

This filing does not contain audited financial statements, revenue, profit, cash flow, or margin data. The primary financial metric disclosed is the authorization of an equity offering with potential aggregate gross proceeds of up to $7,200,000.

Material Changes

On March 27, 2020, the Company entered into an At The Market Offering Agreement (ATM Agreement) with H.C. Wainwright & Co., LLC. Under this agreement, the Company may offer and sell shares of its common stock (trading symbol: NDRA) through Wainwright as sales agent. The offering is subject to a shelf registration statement on Form S-3.

Guidance, Outlook, and Terms

  • Offering Structure: Sales will be made as "at-the-market" equity offerings on or through the Nasdaq Capital Market. The Company may also sell shares to Wainwright as principal or in negotiated transactions with prior approval.
  • Compensation: The Company agreed to pay Wainwright a commission of 3.0% of the aggregate gross proceeds from any shares sold.
  • Flexibility: The Company has no obligation to sell any shares and may suspend offers or terminate the agreement at any time.
  • Termination: The agreement terminates upon the sale of all authorized shares or earlier termination by either party.

Investor Verification Checklist

  • Verify the current trading price of NDRA to assess potential dilution from the $7.2 million offering.
  • Review the Company's most recent 10-K or 10-Q for actual cash position and burn rate to determine the necessity of this financing.
  • Confirm the status of the shelf registration statement (File No. 333-229090) and any subsequent sales activity.
  • Monitor for future 8-K filings detailing the actual volume and price of shares sold under the ATM Agreement.